Why companies do not take random calls from "investors'The following has been reported in Fiercebiotech on why late stage biotech companies don't take unsolicited calls from "investors" further to the rising level of FDA and SEC scrutiny on all companies, as exemplified by the linked report .... “At the macro level, there is an unprecedented level of scrutiny at the FDA. Maybe the most scrutiny we’ve seen since the early 1960s,”
The company Sesen (formerly Eleven Biotechnology) is in the development of antibody drug conjugates (ADC). I had commented on the issues of ADCs on the Yahoo message board before my posts kept being deleted. I also pointed out that ONCY's oncolytic virus pelareorep was able to enable CAR-T and bispecific therapies in solid tumors, making those treatments effective in various forms of solid tumors, by overcoming the immunosuppressive tumor microenvironment (TME), thus turning a cold tumor "hot", and by facilitating T-cell infiltration into the cancer cell, resulting in effective killing of the cancer cell, as several mechanisms of pelareorep's action
https://www.fiercebiotech.com/biotech/sesen-bio-shares-crater-after-repot-trial-misconduct-for-bladder-cancer-drug
Vicinium, a next-generation antibody-drug conjugate, is being developed as an alternative to losing the bladder
https://www.fiercebiotech.com/struggling-eleven-bio-cashes-out-2nd-drug-270m-roche-deal